Clarity is a personalised medicine company focused on the treatment of serious diseases. The Company is a leader in innovative radiopharmaceuticals, developing targeted therapies for the treatment of cancer and other serious diseases in adults and children.
Clarity utilises its strong imaging capability and proprietary technology to develop novel radiopharmaceuticals. Its in-house drug development program is focused on developing targeted therapeutics in oncology using a theranostic approach, which combines diagnostics and therapy. Clarity's lead compound Cu-64/67 SARTATE is a next generation, highly targeted, theranostic medicine under clinical development to diagnose and treat a range of cancers. Cu-64 SARTATE allows for the diagnosis and the potential to personalise treatment. Cu-67 SARTATE enables the treatment of a range of cancers.
SARTATE is currently in Cu-64/67 theranostic trials in meningioma and is entering clinical trials for neuroblastoma, an aggressive childhood cancer. Clarity is in a number of negotiations to expand its program with the prostate cancer market remaining a key focus. Clarity’s technology holds great promise of improving prostate cancer diagnosis and treatment.